Importantly, evolocumab treatment significantly reduced NETs accumulation, reinforcing the concept that PCSK9 inhibition blocked the platelet-neutrophil axis and suppressed thrombophilia. Here, PCSK9 is linked to Rare hereditary thrombophilia.